1
|
Morikawa G, Fukami K, Moriiwa Y, Okazawa K, Yanagida A. Evaluation of the clinical and quantitative performance of a practical HPLC-UV platform for in-hospital routine therapeutic drug monitoring of multiple drugs. J Pharm Health Care Sci 2023; 9:29. [PMID: 37777811 PMCID: PMC10544152 DOI: 10.1186/s40780-023-00298-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Accepted: 07/22/2023] [Indexed: 10/02/2023] Open
Abstract
BACKGROUND In-hospital therapeutic drug monitoring (TDM) requires a suitable quantification method for target drugs from the viewpoint of precision, throughput, and testing costs. We previously developed a practical HPLC-UV platform for quantification of serum levels of various drugs. In this report, the platform was effectively applied to the quantification of patient serum levels of five different drugs by clinical professionals in our hospital during their daily work. METHODS The residual sera of patients receiving carbamazepine (CBZ), phenytoin (PHT), lamotrigine (LTG), vancomycin (VCM), or voriconazole (VRCZ) were used in the present clinical study. The quantification method for each drug consisted of rapid solid-phase extraction (SPE) of each drug in the patient serum, followed by optimized HPLC-UV analysis of the drug in the SPE eluate. Furthermore, patient serum levels of PHT, CBZ, and VCM were also measured by ligand-binding assay using a cobas® analyzer in our hospital, and those of LTG and VRCZ were measured by HPLC-MS/MS at an outsourced provider. Passing-Bablok regression analysis and Bland-Altman analysis were employed to analyze the agreement of drug levels in patient sera, which was separately quantified using two different methods-our HPLC-UV platform and the cobas analyzer, or HPLC-UV and HPLC-MS/MS. RESULTS All analytical conditions of the present method using our HPLC-UV platform were well optimized for each target drug quantification in the patient's serum, and the quantification method for each drug was fully validated for accuracy, precision and reproducibility. Furthermore, Passing-Bablok regression analysis and Bland-Altman analysis revealed that patient serum levels of PHT, CBZ, and VCM quantified by our HPLC-UV platform were closely correlated with those quantified by the cobas® analyzer, and the levels of LTG and VRCZ quantified by our HPLC-UV platform were also correlated with those quantified by HPLC-MS/MS. CONCLUSIONS Our HPLC-UV platform can be performed without requiring special analytical techniques. This platform is expected to be used for the measurement of blood levels of multiple drugs for in-hospital routine TDM.
Collapse
Affiliation(s)
- Go Morikawa
- Department of Pharmacy, Hokushin General Hospital, 1-5-63, Nishi, Nakano, Nagano, 383-8505, Japan.
| | - Kazuto Fukami
- Department of Clinical laboratory, Hokushin General Hospital, 1-5-63, Nishi, Nakano, Nagano, 383-8505, Japan
| | - Yukiko Moriiwa
- Department of Biomedical Analysis, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Katsuko Okazawa
- Department of Pharmacy, Hokushin General Hospital, 1-5-63, Nishi, Nakano, Nagano, 383-8505, Japan
| | - Akio Yanagida
- Department of Biomedical Analysis, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| |
Collapse
|
2
|
Chanduluru HK, Sugumaran A. Assessment of greenness for the determination of voriconazole in reported analytical methods. RSC Adv 2022; 12:6683-6703. [PMID: 35424637 PMCID: PMC8982219 DOI: 10.1039/d1ra08858k] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 02/04/2022] [Indexed: 12/30/2022] Open
Abstract
Analytical research with adverse environmental impact has caused a severe rise in concern about the ecological consequences of its strategies, most notably the use and emission of harmful solvents/reagents into the atmosphere. Nowadays, industries are searching for the best reproducible methods. Voriconazole is a second-generation azole derivative used effectively in the treatment of Candida and Aspergillus species infections and oropharyngeal candidiasis in AIDS patients. Recently it has become the drug of choice in treating mucormycosis in several countries, which raises the need for production in large quantities. The present review deals with various recent important analytical techniques used to estimate voriconazole and its combination in pharmaceutical formulations and biological fluids. The methods show their own unique way of analyzing voriconazole in different matrices with excellent linearity, detection, and quantification limits. Additionally, this article deals with methods and solvents analyzed for their impact on the environment. This is followed by estimating the degree of greenness of the methods using various available assessment tools like analytical eco-scale, national environmental method index, green analytical procedure index, and AGREE metrics to confirm the environmental impact. The scores obtained with the evaluation tools depict the quantum of greenness for the reported methods and provide an ideal approach adopted for VOR estimation. Very few methods are eco-friendly, which shows that there is a need for the budding analyst to develop methods based on green analytical principles to protect the environment.
Collapse
Affiliation(s)
- Hemanth Kumar Chanduluru
- SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur 603203 India +91 7904062599
| | - Abimanyu Sugumaran
- SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur 603203 India +91 7904062599
| |
Collapse
|
3
|
Resztak M, Kosicka K, Zalewska P, Krawiec J, Główka FK. Determination of total and free voriconazole in human plasma: Application to pharmacokinetic study and therapeutic monitoring. J Pharm Biomed Anal 2019; 178:112952. [PMID: 31708268 DOI: 10.1016/j.jpba.2019.112952] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 10/18/2019] [Accepted: 10/21/2019] [Indexed: 01/15/2023]
Affiliation(s)
- Matylda Resztak
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Str., 60-781 Poznań, Poland.
| | - Katarzyna Kosicka
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Str., 60-781 Poznań, Poland.
| | - Paulina Zalewska
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Str., 60-781 Poznań, Poland.
| | - Justyna Krawiec
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Str., 60-781 Poznań, Poland.
| | - Franciszek K Główka
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Str., 60-781 Poznań, Poland.
| |
Collapse
|
4
|
Development of a new stability indicating method for the simultaneous separation of voriconazole from its impurities along with sodium benzoate used as a preservative in a powder for oral suspension. ANNALES PHARMACEUTIQUES FRANÇAISES 2019; 77:394-417. [PMID: 31257019 DOI: 10.1016/j.pharma.2019.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 03/29/2019] [Accepted: 04/02/2019] [Indexed: 11/21/2022]
Abstract
Voriconazole is a second-generation triazole derived from fluconazole, having an enhanced antifungal spectrum, compared with older triazoles. It is the drug of choice for treatment of invasive aspergillosis and many Scedosporium/Pseudallescheria Fusarium infections. Voriconazole is available in both intravenous and oral formulations. Since there is much interest in pharmaceutical quality control, separation of impurities from the main drug substances and accurate assay quantification, and since there is no reference or monograph until nowadays reported for the simultaneous separation of voriconazole from its specified and unspecified impurities along with sodium benzoate used as an antimicrobial preservative, our aim of this work is to develop a new simple, sensitive and stability indicating assay method allowing thus separation by high-performance liquid chromatography. The development of our method consisted in optimizing the following analytical parameters: nature and composition of the mobile phase, its pH, buffer concentration, nature of the stationary phase, column temperature and detection wavelength. After optimisation, separation was achieved on a stainless steel column NOVAPACK C18 (3.9mm×150mm; 4μm particle size) using a gradient mode with methanol, acetonitrile R and an aqueous solution acidified by acetic acid at 1% and adjusted to pH 2.77. The eluted compounds were monitored at 254nm. The flow rate was set at 1.0mL/min, the injection volume at 10μL, and the column oven temperature was maintained at 35°C. Under these conditions, separation was achieved with good resolution and symmetrical peaks' shape. The developed method was validated according to the International Conference on Harmonization (ICH) guidelines, and then it was successfully applied to establish inherent stability of the pharmaceutical formulation subjected to different ICH prescribed stress conditions. The developed method was proved to be simple, specific and precise. Hence, it can be considered as a method for stability study and for routine quality control analysis of voriconazole and sodium benzoate in a powder for oral suspension.
Collapse
|
5
|
Development of a RP-HPLC method for evaluation of in vitro permeability of voriconazole in the presence of enhancers through rat skin. JOURNAL OF SAUDI CHEMICAL SOCIETY 2017. [DOI: 10.1016/j.jscs.2013.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Lemetayer JD, Dowling PM, Taylor SM, Papich MG. Pharmacokinetics and distribution of voriconazole in body fluids of dogs after repeated oral dosing. J Vet Pharmacol Ther 2015; 38:451-6. [DOI: 10.1111/jvp.12208] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 01/16/2015] [Indexed: 01/21/2023]
Affiliation(s)
- J. D. Lemetayer
- Small Animal Clinical Sciences; Western College of Veterinary Medicine; University of Saskatchewan; Saskatoon SK Canada
| | - P. M. Dowling
- Veterinary Biomedical Sciences; Western College of Veterinary Medicine; University of Saskatchewan; Saskatoon SK Canada
| | - S. M. Taylor
- Small Animal Clinical Sciences; Western College of Veterinary Medicine; University of Saskatchewan; Saskatoon SK Canada
| | - M. G. Papich
- Department of Molecular Biomedical Sciences; College of Veterinary Medicine; North Carolina State University; Raleigh NC USA
| |
Collapse
|
7
|
Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, Ohmagari N, Takahashi Y, Kasahara K, Matsumoto K, Okada K, Igarashi M, Kobayashi M, Mochizuki T, Nishi Y, Tanigawara Y, Kimura T, Takesue Y. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 2013; 19:381-92. [PMID: 23673473 PMCID: PMC3682092 DOI: 10.1007/s10156-013-0607-8] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Accepted: 04/15/2013] [Indexed: 11/25/2022]
Affiliation(s)
- Yukihiro Hamada
- Department of Infection Control and Prevention, Aichi Medical University Graduate School of Medicine, Aichi, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Issei Tokimatsu
- Internal Medicine II, Oita University Faculty of Medicine, Oita, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Hiroshige Mikamo
- Department of Infection Control and Prevention, Aichi Medical University Graduate School of Medicine, Aichi, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Masao Kimura
- Department of Pharmacy, Aichi Medical University Hospital, Aichi, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Masafumi Seki
- Division of Infection Control and Prevention, Osaka University Medical Hospital, Osaka, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Shunji Takakura
- Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Yoshiko Takahashi
- Department of Pharmacy, Hyogo Medical College Hospital, Hyogo, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Kei Kasahara
- Center for Infectious Diseases, Nara Medical University, Nara, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Kazuaki Matsumoto
- Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Kenji Okada
- Department of Pharmacy, Tokyo Women’s Medical University Hospital, Tokyo, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Masahiro Igarashi
- Department of Pharmacy, Toranomon Hospital, Tokyo, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Masahiro Kobayashi
- Department of Pharmacy, Kitasato University Hospital, Kanagawa, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Takahiro Mochizuki
- Department of Pharmacy, Shizuoka Cancer Center, Shizuoka, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Yoshifumi Nishi
- Department of Pharmacy, Kyorin University School of Medicine, Tokyo, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Yusuke Tanigawara
- Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Toshimi Kimura
- Department of Pharmacy, Tokyo Women’s Medical University Hospital, Tokyo, Japan
- Sectional Committee of Practice Guidelines for TDM; Antimicrobial agents, the Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
| | - Yoshio Takesue
- Department of Infection Control and Prevention, Hyogo College of Medicine, Hyogo, Japan
- Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| |
Collapse
|
8
|
Kuo IF, Ensom MHH. Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. Can J Hosp Pharm 2012; 62:469-82. [PMID: 22478935 DOI: 10.4212/cjhp.v62i6.845] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Voriconazole is a broad-spectrum, second-generation triazole antifungal agent with demonstrated efficacy in the treatment of invasive fungal infections caused by Aspergillus spp. and Candida spp. Given the characteristically poor prognosis of patients with invasive fungal infections and the protracted duration of treatment required, therapeutic monitoring of voriconazole is, in theory, an attractive method to optimize antifungal therapy. OBJECTIVE To determine the utility of therapeutic drug monitoring for voriconazole. METHODS A previously published decision-making algorithm was used to assess the currently available literature on therapeutic drug monitoring of voriconazole. RESULTS Several analytical methods can be used to quantify plasma or serum concentrations of voriconazole. Reasons for therapeutic monitoring of this drug include wide variability both within and between individuals secondary to drug properties, drug-drug interactions, and disease states. Furthermore, voriconazole follows nonlinear pharmacokinetics with saturable hepatic clearance. Another potential factor in favour of therapeutic drug monitoring for voriconazole is genetic polymorphism of CYP2C19, whereby patients who are homozygous for poor metabolism (about 19% of non-Indian Asians) can have 4-fold greater exposure to voriconazole. The concentrations of this drug are also greater in patients with hepatic impairment. Drug-drug interactions with other substrates of CYP2C9, CYP2C19, and CYP3A4 can also alter voriconazole concentrations. However, the correlations between plasma concentrations of voriconazole and its efficacy and toxicity are not well defined. Although lower and upper target thresholds of 0.25-2 mg/L and 4-6 mg/L, respectively, have been suggested, studies to date have not been appropriately designed or powered to reveal any definitive association. CONCLUSIONS Routine therapeutic drug monitoring of voriconazole is not recommended except in certain circumstances, such as lack of response to therapy or evidence of toxicity, in which case selective monitoring of voriconazole concentrations may be of clinical utility.
Collapse
Affiliation(s)
- I Fan Kuo
- , BSc(Pharm), PharmD, ACPR, was, at the time of writing, a student in the Faculty of Pharmaceutical Sciences, University of British Columbia. She is now a Clinical Pharmacy Specialist at St Paul's Hospital, Vancouver, British Columbia
| | | |
Collapse
|
9
|
Pauwels S, Vermeersch P, Van Eldere J, Desmet K. Fast and simple LC–MS/MS method for quantifying plasma voriconazole. Clin Chim Acta 2012; 413:740-3. [DOI: 10.1016/j.cca.2012.01.008] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 12/21/2011] [Accepted: 01/04/2012] [Indexed: 11/29/2022]
|
10
|
Khetre AB, Sinha PK, Damle MC, Mehendre R. Development and Validation of Stability Indicating RP-HPLC Method for Voriconazole. Indian J Pharm Sci 2011; 71:509-14. [PMID: 20502568 PMCID: PMC2866341 DOI: 10.4103/0250-474x.58178] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Revised: 07/31/2009] [Accepted: 08/25/2009] [Indexed: 11/04/2022] Open
Abstract
This study describes the development and validation of stability indicating HPLC method for voriconazole, an antifungal drug. Voriconazole was subjected to stress degradation under different conditions recommended by International Conference on Harmonization. The sample so generated was used to develop a stability-indicating high performance liquid chromatographic method for voriconazole. The peak for voriconazole was well resolved from peaks of degradation products, using a Hypersil C18 (250x4.6 mm) column and a mobile phase comprising of acetonitrile: water (40:60, v/v), at flow rate of 1 ml/min. Detection was carried out using photodiode array detector. A linear response (r > 0.99) was observed in the range of 5-25 mug/ml. The method showed good recoveries (average 100.06%) and relative standard deviation for intra and inter-day were </= 1.5 %. The method was validated for specificity and robustness also.
Collapse
Affiliation(s)
- A B Khetre
- Department of Pharmaceutical Chemistry, AISSMS College of Pharmacy, Pune-411 001, India
| | | | | | | |
Collapse
|
11
|
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob Agents Chemother 2010; 54:3408-13. [PMID: 20530230 DOI: 10.1128/aac.01807-09] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
We have developed and validated a high-performance liquid chromatography method coupled with a mass detector to quantify itraconazole, voriconazole, and posaconazole using quinoxaline as the internal standard. The method involves protein precipitation with acetonitrile. Mean accuracy (percent deviation from the true value) and precision (relative standard deviation percentage) were less than 15%. Mean recovery was more than 80% for all drugs quantified. The lower limit of quantification was 0.031 microg/ml for itraconazole and posaconazole and 0.039 microg/ml for voriconazole. The calibration range tested was from 0.031 to 8 microg/ml for itraconazole and posaconazole and from 0.039 to 10 microg/ml for voriconazole.
Collapse
|
12
|
Patel CN, Dave JB, Patel JV, Panigrahi B. Validated LC Method for the Estimation of Voriconazole in Bulk and Formulation. Indian J Pharm Sci 2010; 71:699-702. [PMID: 20376229 PMCID: PMC2846481 DOI: 10.4103/0250-474x.59558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2009] [Revised: 09/08/2009] [Accepted: 12/05/2009] [Indexed: 11/04/2022] Open
Abstract
Reversed phase high performance liquid chromatographic method was developed and validated for the estimation of voriconazole in bulk and formulation using prominence diode array detector. Selected mobile phase was a combination of water:acetonitrile (35:65 % v/v) and wavelength selected was 256 nm. Retention time of voriconazole was 3.95 min. Linearity of the method was found to be 0.1 to 2 mug/ml, with the regression coefficient of 0.999. This method was validated according to ICH guidelines. Quantification was done by calculating area of the peak and the detection limit and quantitation limit ware 0.026 mug/ml and 0.1 mug/ml, respectively. There was no significant difference in the intra day and inter day analysis of voriconazole determined for three different concentrations using this method. Present method can be applied for the determination of voriconazole in quality control of formulation without interference of the excipients.
Collapse
Affiliation(s)
- C N Patel
- Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, India
| | | | | | | |
Collapse
|
13
|
Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother 2009; 53:3140-2. [PMID: 19380591 DOI: 10.1128/aac.00213-09] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
A simple, sensitive, and selective high-performance liquid chromatographic method for the simultaneous determination of voriconazole and posaconazole concentrations in human plasma was developed and validated. Quantitative recovery following liquid-liquid extraction with diethyl ether was achieved. Linearity ranged from 0.10 to 20.0 microg/ml for voriconazole and from 0.05 to 10.0 microg/ml for posaconazole. The intra- and interday coefficients of variation were less than 8.5%, and the lower limits of quantitation were <0.05 microg/ml.
Collapse
|
14
|
Adams AIH, Gosmann G, Schneider PH, Bergold AM. LC Stability Studies of Voriconazole and Structural Elucidation of Its Major Degradation Product. Chromatographia 2009. [DOI: 10.1365/s10337-009-1082-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
15
|
Huang X, Qiu F, Cheng S. Development and Validation of an Accurate LC Method for the Quantitative Determination of Voriconazole in a New Emulsion Formulation. Chromatographia 2008. [DOI: 10.1365/s10337-008-0737-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
16
|
Simmel F, Soukup J, Zoerner A, Radke J, Kloft C. Development and validation of an efficient HPLC method for quantification of voriconazole in plasma and microdialysate reflecting an important target site. Anal Bioanal Chem 2008; 392:479-88. [PMID: 18677619 DOI: 10.1007/s00216-008-2286-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2008] [Revised: 06/29/2008] [Accepted: 07/03/2008] [Indexed: 10/21/2022]
Abstract
Voriconazole is a very potent antifungal agent used to treat serious fungal infections (candidiasis); it is also the therapy of choice for aspergillosis. After standard dosing, several factors affect exposure of voriconazole, resulting in large variability and demanding further elucidation of drug distribution. For measurements at the site of action, microdialysis is considered to be an outstanding minimally invasive method. For determination of voriconazole in microdialysate and human plasma a new, efficient, reliable, and robust HPLC assay using UV detection at 254 nm has been developed and validated. After simple sample preparation using acetonitrile for plasma and for microdialysate, 20 microL were injected and separated on an RP-18 column. The chromatographic run time was less than 4 min. Overall, the assay showed high precision (CV 93.9 to 99.5%) and accuracy (RE -96.7 to +107%) for both matrices. Of the 36 drug products typically co-administered with voriconazole, none except ambroxol interfered with its peak signal, and this interference was successfully managed. In summary, the method is highly suitable for application in (pre)clinical microdialysis studies, e.g., of critically ill patients with invasive mycoses.
Collapse
Affiliation(s)
- Franziska Simmel
- Department of Clinical Pharmacy, Institute of Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120, Halle, Germany
| | | | | | | | | |
Collapse
|
17
|
Nakagawa S, Suzuki R, Yamazaki R, Kusuhara Y, Mitsumoto S, Kobayashi H, Shimoeda S, Ohta S, Yamato S. Determination of the antifungal agent voriconazole in human plasma using a simple column-switching high-performance liquid chromatography and its application to a pharmacokinetic study. Chem Pharm Bull (Tokyo) 2008; 56:328-31. [PMID: 18310944 DOI: 10.1248/cpb.56.328] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A simple column-switching high performance liquid chromatographic (HPLC) method that does not require any complicated pretreatment has been developed to determine voriconazole in human plasma samples. An internal standard (IS) and borate buffer (pH 9.0) were added to plasma samples, which were then injected directly into the column-switching HPLC system using MAYI-ODS as a pre-column. The calibration curve for voriconazole showed good linearity in the range of 0.2-10 mug/ml in human plasma. The mean RSD (%) value of intra-day (n=6) and inter-day (n=5) precision were less than 5.4% and 8.2%, respectively. This system could make more than three hundred successive, accurate measurements when a washing step with ammonium acetate solution was added. This method was successfully applied to measure the therapeutic voriconazole level in patients' plasma, and was used in a study of voriconazole pharmacokinetics after oral administration.
Collapse
Affiliation(s)
- Saori Nakagawa
- Department of Bio-analytical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 956-8603, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 865:74-80. [DOI: 10.1016/j.jchromb.2008.02.009] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2007] [Revised: 02/06/2008] [Accepted: 02/17/2008] [Indexed: 11/21/2022]
|
19
|
Eiden C, Mathieu O, Peyrière H, Hillaire-Buys D, Cociglio M. Simultaneous Quantification of Voriconazole and Its N-Oxide Metabolite in Human Plasma by an Easy and Rapid Isocratic LC Method with UV Detection. Chromatographia 2008. [DOI: 10.1365/s10337-007-0508-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
20
|
Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem 2007; 40:1378-85. [PMID: 17931613 DOI: 10.1016/j.clinbiochem.2007.07.024] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2007] [Revised: 06/23/2007] [Accepted: 07/04/2007] [Indexed: 11/28/2022]
Abstract
OBJECTIVES Voriconazole is an antifungal agent structurally related to fluconazole. While regular drug monitoring is not indicated in most patients, it may help guide dosing in patients with reduced hepatic/renal function, on concurrent therapy with drugs that affect CYP2C9, with altered CYP2C9 genotypes, or during adverse drug reactions. Here we describe an HPLC method for determination of voriconazole. METHODS Samples, calibrators and controls were extracted using a liquid/liquid extraction. Chromatographic separation achieved using gradient solvent delivery with detection at 254 nm with a run time of 10 min. Concentration was calculated by comparison of peak height ratio of the drug with that of internal standard (IS) against a standard curve. RESULTS The assay is linear from 0.29 to 57 micromol/L (0.1-20 microg/mL) shows good linearity (y=0.98x+0.36, r(2)=0.9978). The assay has inter- and intra-day precisions of <10%. The stability of the drugs in specimens was tested for up to 7 days at room temperature, for 30 days frozen at -20 degrees C, and through 3 freeze-thaw cycles and was found to be stable under those conditions. CONCLUSIONS This describes a robust method for the determination of voriconazole in serum and plasma.
Collapse
Affiliation(s)
- Loralie J Langman
- Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Hilton 730, 200 First Street SW, Rochester, MN 55905, USA.
| | | |
Collapse
|
21
|
Nagarjuna A, Padmaja Reddy K, Mukkanti K, Suryanarayana MV. A Validated LC Method for Separation and Quantification of Voriconazole and Its Enantiomer. Chromatographia 2007. [DOI: 10.1365/s10337-007-0315-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
22
|
Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852:223-8. [PMID: 17306633 DOI: 10.1016/j.jchromb.2007.01.021] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2006] [Revised: 01/10/2007] [Accepted: 01/12/2007] [Indexed: 10/23/2022]
Abstract
A sensitive and selective high-performance liquid chromatographic (HPLC) method with ultra-violet detection has been developed and validated for the simultaneous determination of posaconazole and voriconazole, two systemic anti-fungal agents. An internal standard diazepam was added to 100 microL of human plasma followed by 3 mL of hexane-methylene chloride (70:30, v/v). The organic layer was evaporated to dryness and the residue was reconstituted with 100 microL of mobile phase before being injected in the chromatographic system. The compounds were separated on a C8 column using sodium potassium phosphate buffer (0.04 M, pH 6.0): acetonitrile:ultrapure water (45:52.5:2.5, v/v/v) as mobile phase. All compounds were detected at a wavelength of 255 nm. The assay was linear and validated over the range 0.2-10.0 mg/L for voriconazole and 0.05-10.0 mg/L for posaconazole. The biases were comprised between -3 and 5% for voriconazole and -2 and 8% for posaconazole. The intra- and inter-day precisions of the method were lower than 8% for the routine quality control (QC). The mean recovery was 98% for voriconazole and 108% for posaconazole. This method provides a useful tool for therapeutic drug monitoring.
Collapse
Affiliation(s)
- Stéphanie Chhun
- Université Paris V, Faculté de Médecine René Descartes, Assistance Publique-Hôpitaux de Paris, Service de Pharmacologie Clinique, Groupe Hospitalier Cochin-Saint-Vincent de Paul, 74-82 avenue Denfert-Rochereau, 75674 Paris Cedex 14, France
| | | | | | | | | | | |
Collapse
|
23
|
Adams AIH, Bergold AM. Development and Validation of a High Performance Liquid Chromatographic Method for the Determination of Voriconazole Content in Tablets. Chromatographia 2005. [DOI: 10.1365/s10337-005-0629-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|